Globally Cannabinoid research and development is in its infancy. CannaPacific is well placed to meet the pharmaceutical and regulatory requirements to develop clinically proven, fully characterised plant-derived cannabinoid products. Our product development and pharmacology team consists of a network of global world-leading scientists.
Cannapacific has recognised the need to associate novel formulations, specific medical conditions and plant science discoveries to drive the creation of meaningful patent estates supported by robust datasets from lab to vial.
The global medical communities and regulatory authorities demand statistically meaningful data to support the prescribing of cannabinoid-based medicines. CP is evolving a publication/IP strategy that will deliver a steady flow of data to position the business as a leading pharmaceutical provider.